Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer
Cancer Biomarkers · 2022-07-18 · 34 (4) · 647-659
DOI: 10.3233/cbm-210490 ↗At a glance
Journal article in Cancer Biomarkers, published on 2022-07-18. Written by Jae Hyeong Kim and 5 co-authors. Institution: Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea. Major MEDLINE topics: Cisplatin, Pancreatic Neoplasms. Cited 17 times so far (Crossref); 31 references. The full text is freely available in PubMed Central.
Abstract (original language)
Pancreatic cancer is an aggressive and lethal cancer with the highest mortality rate. Hence, the development of new targeting and innovative treatment strategies is needed. Recent studies reported that the histone chaperone anti-silencing function 1B (ASF1B) can be used as a diagnosis and prognosis cancer biomarker. However, functional studies of ASF1B in pancreatic cancer have not been performed. This study compared expression levels of ASF1B in pancreatic cancer specimens with those of normal tissues using publicly available online databases. We found that ASF1B was commonly overexpressed in pancreatic cancer specimens, which is associated with poor prognosis. ASF1B downregulation in pancreatic cancer cells reduced their colony formation, proliferation, migration, and invasion abilities, and inhibited MMP9 activity. Furthermore, ASF1B expression downregulation increased cell cycle S-phase arrest and DNA damage though activation of the checkpoint kinases Chk1 and Chk2 pathways. Additionally, increased caspase (caspases-3 and -9) activation and PARP cleavage led to enhanced caspase-dependent apoptosis and improved cisplatin sensitivity. Collectively, our results indicate that ASF1B may serve as a potential biomarker of pancreatic cancer and a novel therapeutic target.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Department of Internal Medicine and Liver Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea.
Cite
APA
Kim, J. H., Youn, Y., Lee, J. C., Kim, J., Ryu, J. K., & Hwang, J. H. (2022). Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Cancer Biomarkers, 34(4), 647-659. https://doi.org/10.3233/cbm-210490
Vancouver
Kim JH, Youn Y, Lee JC, Kim J, Ryu JK, Hwang JH. Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer. Cancer Biomarkers. 2022;34(4):647-659. doi:10.3233/cbm-210490
BibTeX
@article{Kim2022,
author = {Kim, Jae Hyeong and Youn, Yuna and Lee, Jong-Chan and Kim, Jaihwan and Ryu, Ji Kon and Hwang, Jin-Hyeok},
title = {Downregulation of ASF1B inhibits tumor progression and enhances efficacy of cisplatin in pancreatic cancer},
journal = {Cancer Biomarkers},
year = {2022},
volume = {34},
number = {4},
pages = {647--659},
doi = {10.3233/cbm-210490}
}
EUVIMED